Want to see HK:9886 full AI Analyst Report?
Top Page
Dingdang Health Technology Group Ltd.
(9886)
Select Model
Select Model
Rating:56Neutral
Price Target:
HK$0.88
▼(-0.45% Downside)
Action:Reiterated
Date:09/07/26
The score is driven primarily by improving financial performance (stronger TTM revenue growth, sharply narrowed losses, low leverage, and positive operating/free cash flow), but it is held back by still-negative earnings and weakening TTM free cash flow growth. Technically, momentum is modestly positive in the short term (above 20-day DMA with positive MACD) but the longer-term trend remains pressured (below 100/200-day DMAs). Valuation is a headwind because profitability is not yet positive (negative P/E) and there is no dividend yield provided.
Positive Factors
Strong Revenue Reacceleration
The sharp TTM revenue acceleration indicates stronger demand and improving commercial traction across the company’s digital pharmacy and healthcare platform. If sustained, this growth can expand the operating base, improve fixed-cost absorption, and support continued investment in fulfillment and online services.
Negative Factors
Earnings Remain Negative
Although losses have narrowed substantially, the company has not yet established positive earnings or a durable profit buffer. Continued negative earnings leave less capacity to absorb pricing, cost, or execution pressure, and make successful operating leverage essential for strengthening long-term financial resilience.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong Revenue Reacceleration
The sharp TTM revenue acceleration indicates stronger demand and improving commercial traction across the company’s digital pharmacy and healthcare platform. If sustained, this growth can expand the operating base, improve fixed-cost absorption, and support continued investment in fulfillment and online services.
Read all positive factors
Dingdang Health Technology Group Ltd. (9886) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$976.17M
Dividend YieldN/A
Average Volume (3M)364.32K
Price to Earnings (P/E)―
Beta (1Y)1.57
Revenue Growth8.73%
EPS Growth80.38%
CountryHK
Employees2,232
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)-0.05
Shares Outstanding1,240,312,900
10 Day Avg. Volume909,300
30 Day Avg. Volume364,316
Financial Highlights & Ratios
PEG Ratio0.29
Price to Book (P/B)0.75
Price to Sales (P/S)0.26
P/FCF Ratio10.18
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.35
Revenue Forecast (FY)HK$126.42B
Dingdang Health Technology Group Ltd. Business Overview & Revenue Model
Company Description
Dingdang Health Technology Group Ltd. is a digital retail pharmacy firm operating within the People's Republic of China. The company provides online sales of pharmaceutical products alongside medical consultation services. Founded in 2014, it is b...
How the Company Makes Money
Dingdang Health Technology Group Ltd. primarily makes money by selling products and services through its integrated retail-pharmacy and internet-health platforms. Key revenue streams include: (1) Retail sales of pharmaceuticals and health products...
Dingdang Health Technology Group Ltd. Financial Statement Overview
Summary
Income Statement
52
Neutral
Balance Sheet
67
Positive
Cash Flow
61
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.97B | 4.89B | 4.67B | 4.86B | 4.33B | 3.68B |
| Gross Profit | 1.79B | 1.72B | 1.54B | 1.51B | 1.69B | 1.24B |
| EBITDA | 41.74M | -15.83M | -161.59M | -73.35M | -280.87M | -613.63M |
| Net Income | -61.72M | -49.02M | -376.50M | -225.81M | -2.83B | -1.58B |
Balance Sheet | ||||||
| Total Assets | 2.84B | 2.84B | 2.63B | 3.06B | 3.70B | 3.60B |
| Cash, Cash Equivalents and Short-Term Investments | 1.13B | 1.12B | 1.22B | 1.33B | 1.35B | 1.55B |
| Total Debt | 261.79M | 281.81M | 152.61M | 140.21M | 163.14M | 4.81B |
| Total Liabilities | 1.31B | 1.16B | 952.45M | 1.03B | 1.23B | 6.77B |
| Stockholders Equity | 1.53B | 1.66B | 1.66B | 2.24B | 2.19B | -2.61B |
Cash Flow | ||||||
| Free Cash Flow | 99.84M | 122.54M | -36.45M | -25.82M | -264.87M | -408.32M |
| Operating Cash Flow | 116.64M | 154.59M | -11.35M | -5.24M | -230.00M | -372.99M |
| Investing Cash Flow | 446.89M | -811.00M | 156.96M | 104.32M | -353.42M | 306.63M |
| Financing Cash Flow | -181.05M | -109.18M | -121.37M | -130.54M | 232.90M | 1.27B |
Dingdang Health Technology Group Ltd. Technical Analysis
Negative
0.88
Price Trends
0.82
Negative
0.88
Negative
0.93
Negative
Market Momentum
>-0.01
Positive
45.41
Neutral
20.69
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:9886, the sentiment is Negative. The current price of 0.88 is above the 20-day moving average (MA) of 0.82, above the 50-day MA of 0.82, and below the 200-day MA of 0.93, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 45.41 is Neutral, neither overbought nor oversold. The STOCH value of 20.69 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:9886.
Dingdang Health Technology Group Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | HK$2.91B | 9.39 | 8.51% | 7.69% | 25.14% | 39.67% | |
71 Outperform | HK$26.59B | 13.47 | 17.22% | 2.44% | -9.65% | -25.51% | |
56 Neutral | HK$976.17M | -13.91 | -3.87% | ― | 8.73% | 80.38% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | HK$604.46M | -1.51 | -25.36% | 1.47% | -8.94% | -140.82% | |
46 Neutral | HK$900.95M | -15.68 | -12.81% | 0.53% | 13.43% | 7.72% | |
42 Neutral | HK$231.21M | -0.23 | 76.98% | ― | ― | ― |
* Healthcare Sector Average
HK:9886
Dingdang Health Technology Group Ltd.
0.80
-0.05
-5.88%
HK:0399
Innovative Pharmaceutical Biotech
0.07
-0.42
-85.10%
HK:0157
Natural Beauty Bio-Technology
0.45
-0.10
-18.18%
HK:6601
Cheerwin Group Limited
2.17
0.07
3.33%
HK:2138
EC Healthcare
0.51
-0.27
-34.62%
HK:2367
Giant Biogene Holding Co. Ltd.
24.56
-35.62
-59.19%
Dingdang Health Technology Group Ltd. Corporate Events
Dingdang Health Posts Higher Loss but Near-Breakeven Adjusted Results in First Half 2026
Aug 21, 2026
Dingdang Health Technology Group Ltd. reported unaudited interim results for the six months ended June 30, 2026, showing modest revenue growth but widening headline losses.
Revenue rose 3.5% year-on-year to RMB2.41 billion, while loss for the peri...
Dingdang Health Sets August Board Meeting to Approve Interim Results and Consider Dividend
Aug 11, 2026
Dingdang Health Technology Group Ltd. has scheduled a board meeting for August 21, 2026, to review and approve the group’s interim results for the six months ended June 30, 2026, and to authorize their publication. The board will also consid...
Dingdang Health Revamps Board with New Executive Director and Committee Changes
Jul 21, 2026
Dingdang Health Technology Group Ltd. has announced a board reshuffle effective July 21, 2026, with non-executive director Li Chuheng resigning to pursue other business engagements and stepping down from the remuneration and nomination committees....
Dingdang Health Details Board and Committee Structure
Jul 21, 2026
Dingdang Health Technology Group Ltd. has outlined the composition of its board of directors, naming Chairman and President Yang Wenlong alongside five other executive directors and three independent non-executive directors. The announcement under...
Dingdang Health Technology Announces Company Secretary Resignation and Governance Continuity
Jun 26, 2026
Dingdang Health Technology Group Ltd. has announced the resignation of joint company secretary Liu Zhenxuan, effective June 26, 2026, as he plans to focus on other business engagements. The board noted that Liu has no disagreements with the direct...
Dingdang Health Wins Strong Shareholder Backing at Annual Meeting
Jun 23, 2026
Dingdang Health Technology Group Ltd. reported that all resolutions at its June 23 annual general meeting in Beijing were passed by shareholders via poll, including adoption of the 2025 audited financial statements and re-election of key executive...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.